-
-
-
-
-
-
-
Raymond James Reiterates Strong Buy Rating on Biohaven Pharma (BHVN)
-
-
-
-
-
-
-
Canaccord Reiterates Buy Rating on Biohaven Pharma (BHVN)
-
-
-
-
-
-
-
Biohaven Pharma (BHVN) Misses Q2 EPS by 3c
-
-
-
-
-
-
-
Biohaven begins first human trial of brain-penetrant drug BHV-8100
-
-
-
-
-
-
-
Canaccord Starts Biohaven Pharma (BHVN) at Buy
-
-
-
-
-
-
-
Piper Sandler: 'Biohaven Pharma (BHVN) Gearing Up for a Catalyst-Rich 2026'
-
-
-
-
-
-
-
Stifel Reiterates Xenon Pharmaceuticals (XENE) at Buy following Biohaven's failure
-
483,079 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


